Protocol
NMN supplementation
Nicotinamide mononucleotide · NMN · beta-nicotinamide mononucleotide · NMN drip · NAD+ precursor supplementation · NMN IV therapy
NMN reliably does the one thing it is mechanistically supposed to do: multiple placebo-controlled human trials show oral NMN raises circulating NAD+ concentrations dose-dependently and is safe and well tolerated at doses up to 900mg daily. Beyond that, the evidence thins out sharply. Small randomised trials report scattered functional signals: improved walking distance at 30 and 60 days, increased muscle insulin sensitivity in prediabetic women (Yoshino 2021), enhanced aerobic capacity in amateur runners (Liao 2021), and maintained walking speed with improved sleep quality in older adults (Morifuji 2024). These are individually small, short, largely unreplicated, and conducted in heterogeneous populations. Critically, no trial has measured a longevity or a composite healthspan endpoint, and no trial has demonstrated that raising NAD+ produces the downstream ageing benefits the mechanism predicts. The bulk of the compelling ageing-reversal data remains in mice. Singapore's own Centre for Healthy Longevity (Prof. Brian Kennedy and Prof. Andrea Maier, NUHS) has explicitly framed its NMN work around the still-open question of whether supplementation is needed at all in a given individual and what dose makes the NAD+ change clinically meaningful, which is a fair statement of where the field actually sits. Chi Longevity's own copy concedes that "clinical outcomes vary significantly between individuals" and that "generalised supplementation might not produce beneficial results". Intravenous NMN and NAD+ drips rest on a materially weaker footing again: there is no meaningful controlled human outcome evidence for the IV route, and the pharmacokinetic rationale for bypassing oral dosing is not established. Treat oral NMN as a well-characterised NAD+-raising agent in search of a demonstrated clinical benefit, and the drip form as commercial.
At a glance
- Evidence
- Mechanism
- Singapore (HSA)
- Not evaluated or approved by HSA for any indication. Oral NMN is sold in Singapore under HSA's health supplements framework, which imposes no pre-market approval or licensing requirement for importation, manufacture or sale. Dealers self-assess and self-certify that products meet safety, quality and labelling standards, and HSA notification is voluntary. Health supplements must not be labelled, advertised or promoted for any medicinal purpose, including any claim to treat or prevent disease. Chi Longevity carries the corresponding disclaimer that the supplement "has not been evaluated by the HSA for the purpose of diagnosing, treating, curing or preventing any disease". Intravenous NMN and NAD+ preparations sit outside the supplement regime and are a separate and less clear matter: Artisan Regenerative Centre's own page states that the NAD+ preparation it uses "has not yet been recognized in pharmaceutical and medical device laws". No HSA registration of an injectable NMN or NAD+ therapeutic product was verified.
- Australia (TGA)
- As of 10 December 2025, nicotinamide mononucleotide is a permissible ingredient under the Therapeutic Goods (Permissible Ingredients) Determination (No. 4) 2025, meaning it may be used in AUST L listed medicines sold in Australia. The TGA has also published a compositional guideline for NMN setting identity, assay, impurity and microbiological standards. This is a reversal of the prior position, under which NMN could be manufactured in Australia only for export and its domestic status was contested. Important limits: permissible-ingredient status is an ingredient approval, not approval of a medicine for a named indication. Listed medicines containing NMN remain confined to low-level general health claims (for example supporting energy production or general wellbeing) and cannot claim to treat, prevent or cure disease, and cannot make longevity or anti-ageing claims. This applies to oral products. No TGA approval of an injectable or IV NMN or NAD+ product was verified, and the TGA maintains a separate safety alert page concerning NAD, NAD+, NADH and NMN medicines sold in Australia which could not be retrieved during this research.
- Offered at
- 2 clinics
Singapore
Health Sciences Authority
- HSA status
- Not evaluated or approved by HSA for any indication. Oral NMN is sold in Singapore under HSA's health supplements framework, which imposes no pre-market approval or licensing requirement for importation, manufacture or sale. Dealers self-assess and self-certify that products meet safety, quality and labelling standards, and HSA notification is voluntary. Health supplements must not be labelled, advertised or promoted for any medicinal purpose, including any claim to treat or prevent disease. Chi Longevity carries the corresponding disclaimer that the supplement "has not been evaluated by the HSA for the purpose of diagnosing, treating, curing or preventing any disease". Intravenous NMN and NAD+ preparations sit outside the supplement regime and are a separate and less clear matter: Artisan Regenerative Centre's own page states that the NAD+ preparation it uses "has not yet been recognized in pharmaceutical and medical device laws". No HSA registration of an injectable NMN or NAD+ therapeutic product was verified.
- In our SG set
- Tracked in Singapore
- SG clinics
- 2
Australia
Therapeutic Goods Administration
- TGA status
- As of 10 December 2025, nicotinamide mononucleotide is a permissible ingredient under the Therapeutic Goods (Permissible Ingredients) Determination (No. 4) 2025, meaning it may be used in AUST L listed medicines sold in Australia. The TGA has also published a compositional guideline for NMN setting identity, assay, impurity and microbiological standards. This is a reversal of the prior position, under which NMN could be manufactured in Australia only for export and its domestic status was contested. Important limits: permissible-ingredient status is an ingredient approval, not approval of a medicine for a named indication. Listed medicines containing NMN remain confined to low-level general health claims (for example supporting energy production or general wellbeing) and cannot claim to treat, prevent or cure disease, and cannot make longevity or anti-ageing claims. This applies to oral products. No TGA approval of an injectable or IV NMN or NAD+ product was verified, and the TGA maintains a separate safety alert page concerning NAD, NAD+, NADH and NMN medicines sold in Australia which could not be retrieved during this research.
- In our AU set
- Tracked in Australia
- AU clinics
- None on file
Evidence is not approvalAn evidence grade describes how strong the science is. A regulatory status describes whether a body has approved the intervention for an indication. They are different questions, answered separately above.
What it is
Plain-language explainer
NMN (nicotinamide mononucleotide) is a small-molecule precursor to NAD+, a coenzyme central to cellular energy metabolism and DNA repair whose tissue levels decline with age. It is taken orally as a capsule, typically 250mg to 900mg daily, and is also administered by some clinics as an intravenous drip alongside or instead of NAD+ itself. The claim made for it is that restoring NAD+ levels slows or partially reverses age-related cellular decline, though the clinics selling it in this region are notably more guarded than the wider market.
Categories
Protocol
Offered by
Where variis has verified this protocol (2)
Keep reading
Related coverage from the newsroom.
Sources
What this profile is built on
- Regulatory overview of health supplements · Health Sciences Authority (HSA), Singapore
- NMN Supplement (prescribed under the Maier Method) · Chi Longevity
- Artisan Regenerative Centre services (lists Stem Cell Culture Supernatant) · Artisan Regenerative Centre
- Australia's TGA approves NMN ingredient for supplement use · NutraIngredients
- Australia sets the global standard for NMN in therapeutic goods · Nutraceutical Business Review
- NMN in Australia: TGA Status, Standards & ARTG Listings Explained · Eco Traders Australia
- Australia TGA Clears NMN As A Permissible Therapeutic Ingredient · BioPharma APAC
- Singapore's Centre for Healthy Longevity trials NMN, AKG, multivitamins on healthy ageing · NutraIngredients
- Human randomised controlled trials of nicotinamide mononucleotide · PubMed / NCBI
Every entity profile on variis is sourced. Not medical advice.